Electrome Corporation is currently transitioning its strategic partnership with BioElectronics Corporation (BIEL) into the active manufacturing and commercial rollout phase for its AI-driven PAINKILLER™ platform. The biotech startup, which focuses on non-invasive bioelectric therapeutics, has been rapidly expanding its footprint across clinical and consumer sectors.
Latest News & Developments
Commercial Rollout & Manufacturing: The licensing agreement with BioElectronics Corp entered the official execution phase. Manufacturing is underway to power Electrome’s direct-to-consumer launch of ActiPatch® and RecoveryRx® devices through their newly minted digital ecosystem.
AI-Native "PAINKILLER" Platform: Electrome launched its core platform (painkiller.care), which pairs wearable pulsed electromagnetic field (PEMF) therapy with predictive analytics and AI to customize pain-management protocols for musculoskeletal, post-operative, and chronic pain.
Retail & VA Pipeline Expansion: Following early pilot deployments within the U.S. Department of Veterans Affairs (VA), Electrome is aggressively scaling its supply chain to prepare for a massive distribution push into an estimated 3,700 retail pharmacies across North America.
LymeCure™ Research Study: In collaboration with Tulane University, Electrome kicked off a major study using its AI-enabled Dual Discovery Engine to test how tuned bioelectric signals can disrupt pathogen motility and biofilm formation, targeting a non-pharmacological cure for Lyme disease.
Pipeline Rumors & Future Horizons
Pre-Seed Funding Target: Investment circles indicate the Austin-and-LA-based startup is wrapping up its pre-seed funding round with a $3.0 million target to finance its heavy digital marketing and e-commerce push.
Defense & Pharma Cross-Over: CEO Ken Mayer has hinted that the biological data gathered from their ongoing infectious disease and pathogen persistence studies are being positioned for upcoming research and development collaborations with both major pharmaceutical firms and defense agencies.
Oncology & Brain Health Expansion: While the current commercial focus is locked entirely on drug-free pain relief and inflammation, Electrome's internal roadmap includes longer-term clinical exploration into bioelectric therapies for oncology research and brain health.
Latest News & Developments
Commercial Rollout & Manufacturing: The licensing agreement with BioElectronics Corp entered the official execution phase. Manufacturing is underway to power Electrome’s direct-to-consumer launch of ActiPatch® and RecoveryRx® devices through their newly minted digital ecosystem.
AI-Native "PAINKILLER" Platform: Electrome launched its core platform (painkiller.care), which pairs wearable pulsed electromagnetic field (PEMF) therapy with predictive analytics and AI to customize pain-management protocols for musculoskeletal, post-operative, and chronic pain.
Retail & VA Pipeline Expansion: Following early pilot deployments within the U.S. Department of Veterans Affairs (VA), Electrome is aggressively scaling its supply chain to prepare for a massive distribution push into an estimated 3,700 retail pharmacies across North America.
LymeCure™ Research Study: In collaboration with Tulane University, Electrome kicked off a major study using its AI-enabled Dual Discovery Engine to test how tuned bioelectric signals can disrupt pathogen motility and biofilm formation, targeting a non-pharmacological cure for Lyme disease.
Pipeline Rumors & Future Horizons
Pre-Seed Funding Target: Investment circles indicate the Austin-and-LA-based startup is wrapping up its pre-seed funding round with a $3.0 million target to finance its heavy digital marketing and e-commerce push.
Defense & Pharma Cross-Over: CEO Ken Mayer has hinted that the biological data gathered from their ongoing infectious disease and pathogen persistence studies are being positioned for upcoming research and development collaborations with both major pharmaceutical firms and defense agencies.
Oncology & Brain Health Expansion: While the current commercial focus is locked entirely on drug-free pain relief and inflammation, Electrome's internal roadmap includes longer-term clinical exploration into bioelectric therapies for oncology research and brain health.
2
